We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026
Read MoreHide Full Article
Key Takeaways
Abbott's EP sales grew at a mid-to-high-teens rate globally, exceeding 20% in the United States.
ABT's Volt adoption accelerated after its U.S. launch, while Japan's fourth-quarter launch could boost growth.
ABT's TactiFlex Duo approval expands treatment options, but slowing LAA orders may offset ablation growth.
Abbott’s (ABT - Free Report) Medical Devices segment delivered 8% sales growth in the third quarter of 2026, with Electrophysiology (“EP”) serving as a key contributor. Excluding left atrial appendage (LAA) products, EP sales grew at a mid-to-high-teens rate globally and more than 20% in the United States. Adoption of its Volt pulsed field ablation (PFA) catheter accelerated in September following its full U.S. market release in mid-August. International growth also picked up, supported by market share gains in Europe as adoption of Abbott’s new PFA catheters increased, along with growth across other product categories.
The company is also expanding the EP portfolio. In September, Abbott received FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, ahead of schedule. The device allows physicians to use PFA, radiofrequency (RF) energy or a combination of both during a procedure, giving them greater flexibility to tailor treatment to each patient. A broader U.S. launch is expected in the fourth quarter, supported by physicians’ familiarity with the TactiFlex platform. In August, Abbott received CE Mark for the Amulet 360 LAA Occluder, designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue.
Abbott expects the fourth-quarter launch of Volt in Japan to help turn the market from a headwind into a tailwind. Japan has followed a similar adoption pattern to the United States, where demand for PFA technology has grown rapidly. The company also expects Volt to contribute for a full quarter in the U.S. market in the fourth quarter.
However, weakness in the LAA market is creating an increasing headwind for the EP business. U.S. orders slowed almost immediately following CE Mark approval for Amulet 360, as some accounts appear to be delaying purchases while awaiting the new device. Management expects this trend to continue through the fourth quarter, offsetting some of the growth acceleration in the ablation business.
Updates From ABT Peers
Thermo Fisher Scientific (TMO - Free Report) reported third-quarter 2026 revenues of $12.14 billion, up 9% year over year. Profitability also improved, with adjusted operating margin expanding by 120 basis points (bps) to 24.5% and adjusted earnings by 15% to $6.68 per share. Thermo Fisher’s pharma and biotech end market delivered high single-digit growth, driven by the pharma services and clinical research businesses, and the research and safety market channel.
Insulet (PODD - Free Report) reported revenues of $842 million, up nearly 20% year over year, with U.S. sales growing 15% and international revenues rising 33%. New customer starts were balanced between type 1 and type 2 diabetes patients globally, while type 2 patients accounted for more than 40% of new starts in the United States. Insulet’s adjusted gross margin rose 200 bps, adjusted operating margin grew 490 bps, and adjusted earnings per share surged 60% year over year.
ABT’s Price Performance, Valuation & Estimates
Over the past year, ABT shares have plunged 16.5% compared with the industry’s 20.7% decline.
Image Source: Zacks Investment Research
In terms of valuation, Abbott is trading at a forward 12-month Price/Sales (P/S) of 3.54X, above its industry average of 2.30X.
Image Source: Zacks Investment Research
Here’s how consensus estimates for Abbott’s earnings currently stand.
Image: Bigstock
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026
Key Takeaways
Abbott’s (ABT - Free Report) Medical Devices segment delivered 8% sales growth in the third quarter of 2026, with Electrophysiology (“EP”) serving as a key contributor. Excluding left atrial appendage (LAA) products, EP sales grew at a mid-to-high-teens rate globally and more than 20% in the United States. Adoption of its Volt pulsed field ablation (PFA) catheter accelerated in September following its full U.S. market release in mid-August. International growth also picked up, supported by market share gains in Europe as adoption of Abbott’s new PFA catheters increased, along with growth across other product categories.
The company is also expanding the EP portfolio. In September, Abbott received FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, ahead of schedule. The device allows physicians to use PFA, radiofrequency (RF) energy or a combination of both during a procedure, giving them greater flexibility to tailor treatment to each patient. A broader U.S. launch is expected in the fourth quarter, supported by physicians’ familiarity with the TactiFlex platform. In August, Abbott received CE Mark for the Amulet 360 LAA Occluder, designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue.
Abbott expects the fourth-quarter launch of Volt in Japan to help turn the market from a headwind into a tailwind. Japan has followed a similar adoption pattern to the United States, where demand for PFA technology has grown rapidly. The company also expects Volt to contribute for a full quarter in the U.S. market in the fourth quarter.
However, weakness in the LAA market is creating an increasing headwind for the EP business. U.S. orders slowed almost immediately following CE Mark approval for Amulet 360, as some accounts appear to be delaying purchases while awaiting the new device. Management expects this trend to continue through the fourth quarter, offsetting some of the growth acceleration in the ablation business.
Updates From ABT Peers
Thermo Fisher Scientific (TMO - Free Report) reported third-quarter 2026 revenues of $12.14 billion, up 9% year over year. Profitability also improved, with adjusted operating margin expanding by 120 basis points (bps) to 24.5% and adjusted earnings by 15% to $6.68 per share. Thermo Fisher’s pharma and biotech end market delivered high single-digit growth, driven by the pharma services and clinical research businesses, and the research and safety market channel.
Insulet (PODD - Free Report) reported revenues of $842 million, up nearly 20% year over year, with U.S. sales growing 15% and international revenues rising 33%. New customer starts were balanced between type 1 and type 2 diabetes patients globally, while type 2 patients accounted for more than 40% of new starts in the United States. Insulet’s adjusted gross margin rose 200 bps, adjusted operating margin grew 490 bps, and adjusted earnings per share surged 60% year over year.
ABT’s Price Performance, Valuation & Estimates
Over the past year, ABT shares have plunged 16.5% compared with the industry’s 20.7% decline.
Image Source: Zacks Investment Research
In terms of valuation, Abbott is trading at a forward 12-month Price/Sales (P/S) of 3.54X, above its industry average of 2.30X.
Image Source: Zacks Investment Research
Here’s how consensus estimates for Abbott’s earnings currently stand.
Image Source: Zacks Investment Research
Abbott currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.